Provides genetic confirmation of APL. Predict relapse risk and monitor for minimal residual disease post-consolidation therapy.
Assay: Sun, Tue, Thu
- Patient Preparation
- Collect
- Lavender (EDTA) or bone marrow (EDTA).
- Specimen Preparation
- Transport 5 mL whole blood (Min: 1 mL). OR 3 mL bone marrow (Min: 1 mL). Specimens must be received within 48 hours of collection due to lability of RNA.
- Storage/Transport Temperature
- Refrigerated.
- Unacceptable Conditions
- Serum or plasma. Frozen or clotted specimens. Specimens collected in anticoagulants other than EDTA. Severely hemolyzed specimens.
- Remarks
- Stability
- Ambient: 1 hour; Refrigerated: 48 hours; Frozen: Unacceptable
Component Test Code* | Component Chart Name | LOINC |
---|---|---|
2002872 | PML-RARA Translocation, t(15;17) | 21551-7 |
2002874 | PML-RARA Translocation, t(15;17) Quant | 21785-1 |
- AMPL' APL
- APL MRD
- APL Post-consolidation therapy testing
- PML-RARA fusion types, A, B, B variant
- PML-RARA long, short, variable types
- PML-RARA S, L, V forms
- PML_RARA fusion types
- Quantitative PML
- t(15;17)